27 pts (50%) had cycle delays (7–14 days), mainly due to Grado 3 neutropenia (60%).

Most common nonhematologic adverse events:

asthenia (40%) and fatigue (35%).

26 pts (48,2%) still under treatment.

28 pts (51,8%) discontinued treatment, owing to disease progression in 25 pts and toxicities in 3.

Conclusion a clinical benefit was observed in 48,2% of our pts with an adequate tolerance and the adherence to treatment was maintained with acceptable toxicity profile.

IGCS20_1247

242

COMPARED WITH SARS AND MERS, THE PERINATAL OUTCOMES OF PREGNANT WOMEN WITH COVID-19 PRESENTED BETTER PROGNOSIS BASED ON AN UPDATED META-ANALYSIS

X Huang*. *Affiliated Hospital of Fujian Medical University, China*

10.1136/ijgc-2020-IGCS.208

Background The novel coronavirus disease (COVID-19), which is caused by a novel beta-coronavirus, SARS-CoV-2, has posed significant public health threats worldwide. We aimed to summarize and compare the effects of SARS, MERS, and COVID-19 on perinatal outcomes.

Methods We search for articles that reported the association between pregnancy and SARS, MERS, or COVID-19 in five databases. A meta-analysis was performed to calculate the pooled prevalence and 95% confidence interval (95% CI).

Results 27 papers involving 106 patients and five unreported cases of pregnant women with COVID-19 were included. The pooled estimate of fatality rates in the SARS and MERS groups were 25% (95% CI 0.01, 0.49) and 40% (95% CI -0.03, 0.83), respectively, whereas only one pregnant women in the COVID-19 group reported death. Stillbirth were more frequent in the SARS (20%, 95% CI -0.15, 0.55) and MERS groups (40%, 95% CI -0.03, 0.83) than COVID-19 group (8%, 95% CI -0.07, 0.23), and the incidence rate of PROM was the same in SARS (20%, 95% CI -0.15, 0.55) and COVID-19 groups (20%, 95% CI 0.09, 0.30). However, the rate of premature delivery of pregnancies was higher in the COVID-19 group (46%, 95% CI 0.30, 0.61) than in the SARS group (35%, 95% CI 0.12, 0.58). There were no confirmed cases of vertical transmission in pregnant women with SARS, MERS, or COVID-19.

Conclusions The condition of pregnant women with COVID-19 was slightly milder than that of pregnant women with SARS and MERS.

IGCS20_1250

244

COST-EFFECTIVENESS OF PREOPERATIVE TYPE AND SCREEN IN PATIENTS UNDERGOING LAPAROSCOPIC HYSTERECTOMY

H Haber*, A Pelletier, S Leung, C Feltmate. *Brigham and Women's Hospital, USA*

10.1136/ijgc-2020-IGCS.209

Intro Preoperative type and screen (T&S) is traditionally ordered for patients undergoing laparoscopic hysterectomy. We aimed to evaluate if it is cost-effective and clinically warranted in this population.

Methods A retrospective case-control study was conducted of all patients who underwent laparoscopic hysterectomy at a tertiary care center and its associated referral hospital between 01/01/2001 and 09/01/2019. Cases were defined as patients who received a perioperative red blood cell transfusion (72 hours before or after surgery). Differences between groups were analyzed using an independent samples t-test for means, Wilcoxon rank sum test for medians, and chi-square for categorical variables.

Results Among 8,321 patients who underwent laparoscopic hysterectomy, 61 (0.73%) had a perioperative transfusion. Age and smoking status were similar between groups; however, cases were more likely to be African-American, Asian and have a body mass index greater than 30 ($p < 0.05$). Of those transfused, 23 (37.1%) were intraoperatively (seven for preoperative anemia, 13 for large blood loss, two for vascular injury and one for unknown reasons). Conversion to laparotomy occurred in 27 cases, of which five underwent transfusion. Only four transfusions (0.05% of hysterectomies) were performed urgently where un-crossmatched O-negative blood would have been required. Eliminating T&S in this population would have saved \$624,075 to \$832,100 during the study period.

Conclusion/Implications Routine T&S is not cost-effective nor clinically useful for the majority of patients undergoing laparoscopic hysterectomy. Further analysis might identify a subset of patients who are at higher risk of blood loss and would benefit from a T&S.

IGCS20_1252

245

THE METAXAS'S HOSPITAL THROMBOPROPHYLAXIS PROGRAM IN ONCOLOGICAL & SURGICAL PATIENTS – METHOS [CLINICALTRIALS.GOV: NCT04248348]. INTERMEDIATE RESULTS FOR GYNECOLOGICAL CANCER PATIENTS UNDERGOING SURGERY

A Fotiou*, V Psomiadou, S Lekka, D Giannouloupoulos, E Geramani, K Kokkali, E Karavioti, D Korfiatis, C Iavazzo, G Vorgias. *Department of Gynecology, 'Metaxa' Memorial Cancer Hospital, Greece*

10.1136/ijgc-2020-IGCS.210

Introduction Compared to benign disease, gynecologic cancer surgery has 6-fold higher risk for DVT and 14-fold for PE. Estimated DVT risk was reported 15–40% in major gynecologic procedures without thromboprophylaxis.

Methods MeTHOS is a prospective observational study aiming to evaluate a possible reduction of VTE risk in High Thrombotic Burden (HTB) gynecological cancer patients undergoing surgery. Women receiving postoperatively tinzaparin (8,000 Anti-Xa IU, OD) were enrolled after signing informed consent.

Results Intermediate results from 97 women are reported. Major characteristics are depicted in table 1.

Major operations were performed in women with higher BMI ($p = 0.0067$) while severe and extremely severe ones in women with lower BMI, and younger age ($p = 0.0257$) (see

Abstract 245 Table 1 Characteristics of the study parameters, percentages are for the study population (N=97)

Characteristic (Median [range] or %)		Cancer sites		FIGO stage		Surgery type	
Age (years)	62 [34-86]	Endometrium	37%	I	55%	Major (2-3 hours)	52%
BMI (Kgr/m ²)	30 [19-49]	Ovarian	31%	II	11%	Severe (3-5 hours)	38%
Heart disease issues	51%	Cervical	14%	III	26%	Extremely severe (>5 hours)	10%
Smoking	31%	Sarcomas	7%	IV	8%		
Alcohol	5%	Vulvar	7%				
Central venous catheter	31%

Abstract 245 Figure 1 Box and whisker plots for operation type vs. BMI and women age. Top and bottom of boxes indicate 25th and 75th percentiles, line within boxes indicate median value, diamond symbol indicates mean value and ends of whiskers are for minimum and maximum value (after exclusion of outliers, circles). For both Kruskal-Wallis comparisons: $p < 0.05$.

figure 1). Extended duration surgeries required in FIGO III-IV stages compared to I-II (70%, 53% respectively, OR:2.1, $p=0.1366$), in ovarian and endometrial cases (73%, 47% respectively, OR:3.1, $p=0.0317$).

Median thromboprophylaxis duration was 31 days (27–35) and was not related to surgery duration ($p > 0.05$). Three PE events occurred (3%), two in women >70 years and BMI >30 and one in a severe surgery. No bleeding events related to thromboprophylaxis were recorded.

Conclusions Higher BMI limited the possibilities to achieve extended surgical goals while younger age favored it. Intense postoperative thromboprophylaxis with tinzaparin (8,000IU) for 1 month, for women with active gynecological cancer and HTB (high BMI & age, >2 hours surgery, comorbidities, advanced FIGO stage) was effective and safe. Further research is needed.

IGCS20_1253

246

RESTRAINT STRESS PROMOTES TUMOR GROWTH IN A SYNGENEIC MOUSE MODEL OF OVARIAN CANCER

¹A Aquino-Acevedo*, ¹C Colón-Echevarría, ¹L Maldonado-Laboy, ²M Bonilla-Claudio, ²GN Armaiz-Pena. ¹Department of Basic Sciences, Division of Pharmacology, School of Medicine, Ponce Health Sciences University, Puerto Rico; ²Divisions of Cancer Biology and Women's Health, Ponce Research Institute, Puerto Rico

10.1136/ijgc-2020-IGCS.211

There is growing evidence that links chronic stress to ovarian cancer (OC) progression. Cancer diagnosis, chemotherapy, and other traumatic life events can lead to altered psychological states, such as chronic stress. Chronic stress induces sustained activation of the sympathetic nervous system (SNS), releasing stress hormones that modulate physiological responses across different systems, including the immune system. Specifically, chronic SNS activation alters the distribution of T-cells, thus influencing clinical outcomes. The aim of this work was to determine the effects of restraint stress on a syngeneic mouse model of OC and characterize its effects on T-cell responses. We hypothesized that restraint stress would lead to accelerated growth of existing tumors and deregulation T-cell subpopulations, promoting an immunosuppressed tumor microenvironment. To determine the effect of daily restraint stress on tumor progression, we used 8 to 12-week-old female C57/BL6 mice. After three days of daily restraint stress, mice were injected with IG10 or ID8 (1×10^6 cells/ 100μL) murine ovarian cancer cells. Mice were sacrificed 8–12 weeks after inoculation. Once sacrificed, tumors were removed and weighted. Our results indicate that daily restraint stress increased OC growth in both IG10/ID8 groups. Moreover, IG10 tumor-bearing mice showed increased ascites production. These results suggest an association between psychological factors and disease progression. Future experiments will assess the effects of chronic stress on T-cell maturation, effector functions, exhaustion, and activation in these samples. Results obtained from this project will support future in vivo experiments regarding the effect of restraint stress and immunotherapy efficacy.